These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Utah
|
|
87-0327982
|
|
(State or other jurisdiction of
|
|
(IRS Employer
|
|
incorporation or organization)
|
|
Identification No.)
|
|
Large accelerated filer
o
|
|
Accelerated filer
x
|
|
|
|
|
|
Non-accelerated filer
o
|
|
Smaller reporting company
o
|
|
(Do not check if a smaller reporting company)
|
|
|
|
|
|
Emerging growth company
o
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
•
|
changes in laws and regulations, or their interpretation, applicable to direct selling or the nutritional supplement industry may prohibit or restrict the Company's ability to sell its products in some markets or require the Company to make changes to its business model in some markets;
|
|
•
|
extensive government regulations to which the Company's products, business practices and manufacturing activities are subject;
|
|
•
|
legal challenges to the Company's direct selling program or to the classification of its independent distributors;
|
|
•
|
effect of complex legal and regulatory requirements, particularly in China and South Korea;
|
|
•
|
impact of anti-bribery laws, including the U.S. Foreign Corrupt Practices Act;
|
|
•
|
its ability to attract and retain independent distributors;
|
|
•
|
the loss of one or more key independent distributors who have a significant sales network;
|
|
•
|
the full implementation of its joint venture for operations in China with Fosun Industrial Co., Ltd.;
|
|
•
|
registration of products for sale in China, or difficulty or increased cost of importing products into China;
|
|
•
|
cyber security threats and exposure to data loss;
|
|
•
|
reliance on information technology infrastructure;
|
|
•
|
the effect of fluctuating foreign exchange rates;
|
|
•
|
liabilities and obligations arising from improper activity by its independent distributors;
|
|
•
|
its relationship with, and its inability to control the actions of, its independent distributors, and other third parties with whom it does business;
|
|
•
|
changes to its independent distributor compensation plans;
|
|
•
|
geopolitical issues and conflicts;
|
|
•
|
negative consequences resulting from difficult economic conditions, including the availability of liquidity or the willingness of its customers to purchase products;
|
|
•
|
risks associated with the manufacturing of the Company's products;
|
|
•
|
uncertainties relating to the application of transfer pricing, duties, value-added taxes, and other tax regulations, and changes thereto;
|
|
•
|
changes in tax laws, treaties or regulations, or their interpretation, including the impact of the Tax Cuts and Jobs Act;
|
|
•
|
availability and integrity of raw materials;
|
|
•
|
the competitive nature of its business and the nutritional supplement industry;
|
|
•
|
negative publicity related to its products, ingredients, or direct selling organization and the nutritional supplement industry;
|
|
•
|
product liability claims;
|
|
•
|
the sufficiency of trademarks and other intellectual property rights; and
|
|
•
|
reliance on third-parties to distribute its products and provide support services to independent distributors.
|
|
|
March 31,
2018 |
|
December 31,
2017 |
||||
|
Assets
|
|
|
|
|
|
||
|
Current assets:
|
|
|
|
|
|
||
|
Cash and cash equivalents
|
$
|
42,303
|
|
|
$
|
42,910
|
|
|
Accounts receivable, net of allowance for doubtful accounts of $440 and $395, respectively
|
8,259
|
|
|
8,888
|
|
||
|
Assets held for sale
|
998
|
|
|
998
|
|
||
|
Inventories
|
43,655
|
|
|
44,047
|
|
||
|
Prepaid expenses and other
|
5,693
|
|
|
5,666
|
|
||
|
Total current assets
|
100,908
|
|
|
102,509
|
|
||
|
|
|
|
|
||||
|
Property, plant and equipment, net
|
67,094
|
|
|
69,106
|
|
||
|
Investment securities - trading
|
1,753
|
|
|
1,980
|
|
||
|
Intangible assets, net
|
686
|
|
|
709
|
|
||
|
Deferred income tax assets
|
8,354
|
|
|
8,283
|
|
||
|
Other assets
|
12,755
|
|
|
12,608
|
|
||
|
|
$
|
191,550
|
|
|
$
|
195,195
|
|
|
|
|
|
|
||||
|
Liabilities and Shareholders’ Equity
|
|
|
|
|
|
||
|
Current liabilities:
|
|
|
|
|
|
||
|
Accounts payable
|
$
|
5,143
|
|
|
$
|
4,215
|
|
|
Accrued volume incentives and service fees
|
20,064
|
|
|
18,774
|
|
||
|
Accrued liabilities
|
24,594
|
|
|
24,980
|
|
||
|
Deferred revenue
|
2,279
|
|
|
3,348
|
|
||
|
Related party note
|
1,013
|
|
|
506
|
|
||
|
Income taxes payable
|
1,598
|
|
|
1,834
|
|
||
|
Total current liabilities
|
54,691
|
|
|
53,657
|
|
||
|
|
|
|
|
||||
|
Liability related to unrecognized tax benefits
|
4,715
|
|
|
4,633
|
|
||
|
Long-term debt and revolving credit facility
|
7,725
|
|
|
13,181
|
|
||
|
Deferred compensation payable
|
1,753
|
|
|
1,980
|
|
||
|
Long-term deferred income tax liabilities
|
783
|
|
|
770
|
|
||
|
Other liabilities
|
872
|
|
|
1,242
|
|
||
|
Total liabilities
|
70,539
|
|
|
75,463
|
|
||
|
|
|
|
|
||||
|
Shareholders’ equity:
|
|
|
|
|
|
||
|
Common stock, no par value, 50,000 shares authorized, 19,046 and 18,919 shares issued and outstanding, respectively
|
131,830
|
|
|
131,525
|
|
||
|
Accumulated deficit
|
(720
|
)
|
|
(2,072
|
)
|
||
|
Noncontrolling interests
|
246
|
|
|
411
|
|
||
|
Accumulated other comprehensive loss
|
(10,345
|
)
|
|
(10,132
|
)
|
||
|
Total shareholders’ equity
|
121,011
|
|
|
119,732
|
|
||
|
|
$
|
191,550
|
|
|
$
|
195,195
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
Net sales
|
$
|
87,342
|
|
|
$
|
83,098
|
|
|
Cost of sales
|
(22,713
|
)
|
|
(21,728
|
)
|
||
|
Gross profit
|
64,629
|
|
|
61,370
|
|
||
|
|
|
|
|
||||
|
Operating expenses:
|
|
|
|
|
|
||
|
Volume incentives
|
31,362
|
|
|
28,983
|
|
||
|
Selling, general and administrative
|
32,386
|
|
|
30,336
|
|
||
|
Operating income
|
881
|
|
|
2,051
|
|
||
|
Other income, net
|
740
|
|
|
1,275
|
|
||
|
Income before provision for income taxes
|
1,621
|
|
|
3,326
|
|
||
|
Provision for income taxes
|
1,288
|
|
|
1,463
|
|
||
|
Net income
|
333
|
|
|
1,863
|
|
||
|
Net loss attributable to noncontrolling interests
|
(165
|
)
|
|
(297
|
)
|
||
|
Net income attributable to common shareholders
|
$
|
498
|
|
|
$
|
2,160
|
|
|
|
|
|
|
||||
|
Basic and diluted net income per common share:
|
|
|
|
|
|
||
|
|
|
|
|
||||
|
Basic earnings per share attributable to common shareholders
|
$
|
0.03
|
|
|
$
|
0.11
|
|
|
|
|
|
|
||||
|
Diluted earnings per share attributable to common shareholders
|
$
|
0.03
|
|
|
$
|
0.11
|
|
|
|
|
|
|
||||
|
Weighted average basic common shares outstanding
|
19,010
|
|
|
18,845
|
|
||
|
Weighted average diluted common shares outstanding
|
19,353
|
|
|
19,260
|
|
||
|
|
|
|
|
||||
|
Dividends declared per common share
|
$
|
—
|
|
|
$
|
0.10
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
Net income
|
$
|
333
|
|
|
$
|
1,863
|
|
|
Foreign currency translation (loss) gain (net of tax)
|
(213
|
)
|
|
912
|
|
||
|
Total comprehensive income
|
$
|
120
|
|
|
$
|
2,775
|
|
|
|
Common Stock
|
|
Accumulated
Deficit
|
|
Noncontrolling
Interests
|
|
Accumulated
Other
Comprehensive
Loss
|
|
Total
|
|||||||||||||
|
|
Shares
|
|
Value
|
|
|
|
|
|||||||||||||||
|
Balance at December 31, 2017 (as reported)
|
18,919
|
|
|
$
|
131,525
|
|
|
$
|
(2,072
|
)
|
|
$
|
411
|
|
|
$
|
(10,132
|
)
|
|
$
|
119,732
|
|
|
Cumulative effect of change in accounting principle
|
—
|
|
|
—
|
|
|
854
|
|
|
—
|
|
|
—
|
|
|
854
|
|
|||||
|
Balance at January 1, 2018 (as adjusted)
|
18,919
|
|
|
131,525
|
|
|
(1,218
|
)
|
|
411
|
|
|
(10,132
|
)
|
|
120,586
|
|
|||||
|
Share-based compensation expense
|
—
|
|
|
543
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
543
|
|
|||||
|
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax
|
127
|
|
|
(238
|
)
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(238
|
)
|
|||||
|
Net income (loss)
|
—
|
|
|
—
|
|
|
498
|
|
|
(165
|
)
|
|
—
|
|
|
333
|
|
|||||
|
Other comprehensive loss
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(213
|
)
|
|
(213
|
)
|
|||||
|
Balance at March 31, 2018
|
19,046
|
|
|
$
|
131,830
|
|
|
$
|
(720
|
)
|
|
$
|
246
|
|
|
$
|
(10,345
|
)
|
|
$
|
121,011
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
||
|
Net income
|
$
|
333
|
|
|
$
|
1,863
|
|
|
Adjustments to reconcile net income to net cash provided by operating activities:
|
|
|
|
|
|
||
|
Provision for doubtful accounts
|
46
|
|
|
(22
|
)
|
||
|
Depreciation and amortization
|
2,601
|
|
|
1,451
|
|
||
|
Share-based compensation expense
|
543
|
|
|
778
|
|
||
|
Gain on sale of property and equipment
|
—
|
|
|
(16
|
)
|
||
|
Deferred income taxes
|
(46
|
)
|
|
263
|
|
||
|
Purchase of trading investment securities
|
(50
|
)
|
|
(266
|
)
|
||
|
Proceeds from sale of trading investment securities
|
265
|
|
|
33
|
|
||
|
Realized and unrealized (gains) losses on investments
|
23
|
|
|
(49
|
)
|
||
|
Foreign exchange gains
|
(967
|
)
|
|
(1,303
|
)
|
||
|
Changes in assets and liabilities:
|
|
|
|
|
|
||
|
Accounts receivable
|
683
|
|
|
(926
|
)
|
||
|
Inventories
|
856
|
|
|
(850
|
)
|
||
|
Prepaid expenses and other current assets
|
18
|
|
|
(186
|
)
|
||
|
Other assets
|
27
|
|
|
88
|
|
||
|
Accounts payable
|
957
|
|
|
346
|
|
||
|
Accrued volume incentives and service fees
|
1,062
|
|
|
2,471
|
|
||
|
Accrued liabilities
|
(1,148
|
)
|
|
(3,466
|
)
|
||
|
Deferred revenue
|
(1,069
|
)
|
|
293
|
|
||
|
Income taxes payable
|
(261
|
)
|
|
(70
|
)
|
||
|
Liability related to unrecognized tax benefits
|
68
|
|
|
59
|
|
||
|
Deferred compensation payable
|
(227
|
)
|
|
283
|
|
||
|
Net cash provided by operating activities
|
3,714
|
|
|
774
|
|
||
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
||
|
Purchases of property, plant and equipment
|
(489
|
)
|
|
(2,711
|
)
|
||
|
Proceeds from sale of property, plant and equipment
|
—
|
|
|
522
|
|
||
|
Net cash used in investing activities
|
(489
|
)
|
|
(2,189
|
)
|
||
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
||
|
Payments of cash dividends
|
—
|
|
|
(1,886
|
)
|
||
|
Principal payments of new revolving credit facility
|
(5,456
|
)
|
|
—
|
|
||
|
Net borrowings on previous revolving credit facility
|
—
|
|
|
3,341
|
|
||
|
Proceeds from borrowings on related party note
|
500
|
|
|
—
|
|
||
|
Net proceeds from the exercise of stock options
|
(238
|
)
|
|
—
|
|
||
|
Payment of withholding taxes related to the vesting of restricted stock units
|
—
|
|
|
(512
|
)
|
||
|
Net cash (used in) provided by financing activities
|
(5,194
|
)
|
|
943
|
|
||
|
Effect of exchange rates on cash and cash equivalents
|
1,362
|
|
|
1,248
|
|
||
|
Net (decrease) increase in cash and cash equivalents
|
(607
|
)
|
|
776
|
|
||
|
Cash and cash equivalents at the beginning of the period
|
42,910
|
|
|
32,284
|
|
||
|
Cash and cash equivalents at the end of the period
|
$
|
42,303
|
|
|
$
|
33,060
|
|
|
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
|
|
|
|
|
|
||
|
Cash paid for income taxes
|
$
|
1,519
|
|
|
$
|
1,180
|
|
|
Cash paid for interest
|
103
|
|
|
94
|
|
||
|
|
March 31,
2018 |
|
December 31,
2017 |
||||
|
Raw materials
|
$
|
9,744
|
|
|
$
|
9,522
|
|
|
Work in progress
|
2,168
|
|
|
2,153
|
|
||
|
Finished goods
|
31,743
|
|
|
32,372
|
|
||
|
Total inventory
|
$
|
43,655
|
|
|
$
|
44,047
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
Net income attributable to common shareholders:
|
$
|
498
|
|
|
$
|
2,160
|
|
|
|
|
|
|
||||
|
Basic weighted average shares outstanding
|
19,010
|
|
|
18,845
|
|
||
|
|
|
|
|
||||
|
Basic earnings per share attributable to common shareholders:
|
$
|
0.03
|
|
|
$
|
0.11
|
|
|
|
|
|
|
||||
|
Diluted shares outstanding
|
|
|
|
|
|
||
|
Basic weighted-average shares outstanding
|
19,010
|
|
|
18,845
|
|
||
|
Stock-based awards
|
343
|
|
|
415
|
|
||
|
Diluted weighted-average shares outstanding
|
19,353
|
|
|
19,260
|
|
||
|
|
|
|
|
||||
|
Diluted earnings per share attributable to common shareholders:
|
$
|
0.03
|
|
|
$
|
0.11
|
|
|
|
|
|
|
||||
|
Potentially dilutive shares excluded from diluted-per-share amounts:
|
|
|
|
|
|
||
|
Stock options
|
155
|
|
|
224
|
|
||
|
|
|
|
|
||||
|
Potentially anti-dilutive shares excluded from diluted-per-share amounts:
|
|
|
|
|
|
||
|
Stock options
|
1,148
|
|
|
1,201
|
|
||
|
|
Number of
Shares
|
|
Weighted Average
Exercise
Price Per Share
|
|||
|
Options outstanding at December 31, 2017
|
1,390
|
|
|
$
|
12.20
|
|
|
Granted
|
—
|
|
|
—
|
|
|
|
Forfeited or canceled
|
(65
|
)
|
|
16.80
|
|
|
|
Exercised
|
(30
|
)
|
|
5.88
|
|
|
|
Options outstanding at March 31, 2018
|
1,295
|
|
|
12.12
|
|
|
|
|
Number of
Shares
|
|
Weighted Average
Grant Date
Fair Value
|
|||
|
Restricted Stock Units outstanding at December 31, 2017
|
728
|
|
|
$
|
11.56
|
|
|
Granted
|
203
|
|
|
11.30
|
|
|
|
Forfeited
|
—
|
|
|
—
|
|
|
|
Issued
|
(138
|
)
|
|
12.53
|
|
|
|
Restricted Stock Units outstanding at March 31, 2018
|
793
|
|
|
11.32
|
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
Net sales:
|
|
|
|
|
|
||
|
NSP Americas
|
$
|
41,872
|
|
|
$
|
44,645
|
|
|
NSP Russia, Central and Eastern Europe
|
9,551
|
|
|
8,446
|
|
||
|
Synergy WorldWide
|
31,817
|
|
|
27,313
|
|
||
|
NSP China
|
4,102
|
|
|
2,694
|
|
||
|
Total net sales
|
87,342
|
|
|
83,098
|
|
||
|
|
|
|
|
||||
|
Contribution margin (1):
|
|
|
|
|
|
||
|
NSP Americas
|
17,335
|
|
|
19,195
|
|
||
|
NSP Russia, Central and Eastern Europe
|
3,204
|
|
|
2,924
|
|
||
|
Synergy WorldWide
|
9,508
|
|
|
8,199
|
|
||
|
NSP China
|
3,220
|
|
|
2,069
|
|
||
|
Total contribution margin
|
33,267
|
|
|
32,387
|
|
||
|
|
|
|
|
||||
|
Selling, general and administrative (2)
|
32,386
|
|
|
30,336
|
|
||
|
Operating income
|
881
|
|
|
2,051
|
|
||
|
|
|
|
|
||||
|
Other income, net
|
740
|
|
|
1,275
|
|
||
|
Income before provision for income taxes
|
$
|
1,621
|
|
|
$
|
3,326
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
Net sales:
|
|
|
|
|
|
||
|
United States
|
$
|
35,227
|
|
|
$
|
37,735
|
|
|
South Korea
|
14,584
|
|
|
11,346
|
|
||
|
Other
|
37,531
|
|
|
34,017
|
|
||
|
|
$
|
87,342
|
|
|
$
|
83,098
|
|
|
|
Three Months Ended
March 31, |
||||||
|
|
2018
|
|
2017
|
||||
|
NSP Americas:
|
|
|
|
|
|
||
|
General health
|
$
|
17,746
|
|
|
$
|
19,866
|
|
|
Immune
|
5,544
|
|
|
5,073
|
|
||
|
Cardiovascular
|
3,100
|
|
|
3,316
|
|
||
|
Digestive
|
11,712
|
|
|
12,148
|
|
||
|
Personal care
|
1,825
|
|
|
1,886
|
|
||
|
Weight management
|
1,945
|
|
|
2,356
|
|
||
|
|
41,872
|
|
|
44,645
|
|
||
|
NSP Russia, Eastern and Central Europe:
|
|
|
|
|
|
||
|
General health
|
$
|
4,131
|
|
|
$
|
3,943
|
|
|
Immune
|
1,029
|
|
|
862
|
|
||
|
Cardiovascular
|
695
|
|
|
595
|
|
||
|
Digestive
|
2,431
|
|
|
2,088
|
|
||
|
Personal care
|
960
|
|
|
642
|
|
||
|
Weight management
|
305
|
|
|
316
|
|
||
|
|
9,551
|
|
|
8,446
|
|
||
|
Synergy WorldWide:
|
|
|
|
|
|
||
|
General health
|
$
|
8,640
|
|
|
$
|
6,687
|
|
|
Immune
|
149
|
|
|
121
|
|
||
|
Cardiovascular
|
13,330
|
|
|
11,103
|
|
||
|
Digestive
|
3,825
|
|
|
3,465
|
|
||
|
Personal care
|
2,140
|
|
|
2,067
|
|
||
|
Weight management
|
3,733
|
|
|
3,870
|
|
||
|
|
31,817
|
|
|
27,313
|
|
||
|
NSP China:
|
|
|
|
|
|
||
|
General health
|
$
|
343
|
|
|
$
|
495
|
|
|
Immune
|
146
|
|
|
47
|
|
||
|
Cardiovascular
|
561
|
|
|
517
|
|
||
|
Digestive
|
2,456
|
|
|
1,431
|
|
||
|
Personal care
|
253
|
|
|
42
|
|
||
|
Weight management
|
343
|
|
|
162
|
|
||
|
|
4,102
|
|
|
2,694
|
|
||
|
|
$
|
87,342
|
|
|
$
|
83,098
|
|
|
|
March 31,
2018 |
|
December 31,
2017 |
||||
|
Property, plant and equipment:
|
|
|
|
|
|
||
|
United States
|
$
|
64,032
|
|
|
$
|
65,928
|
|
|
Other
|
3,062
|
|
|
3,178
|
|
||
|
Total property, plant and equipment
|
$
|
67,094
|
|
|
$
|
69,106
|
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
|
||||||||
|
|
Quoted Prices
in Active Markets for Identical Assets |
|
Significant
Other Observable Inputs |
|
Significant
Unobservable Inputs |
|
Total
|
||||||||
|
Investment securities - trading
|
$
|
1,753
|
|
|
—
|
|
|
—
|
|
|
$
|
1,753
|
|
||
|
Total assets measured at fair value on a recurring basis
|
$
|
1,753
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,753
|
|
|
|
Level 1
|
|
Level 2
|
|
Level 3
|
|
|
||||||||
|
|
Quoted Prices
in Active
Markets for
Identical Assets
|
|
Significant
Other
Observable
Inputs
|
|
Significant
Unobservable
Inputs
|
|
Total
|
||||||||
|
Investment securities - trading
|
$
|
1,980
|
|
|
—
|
|
|
—
|
|
|
$
|
1,980
|
|
||
|
Total assets measured at fair value on a recurring basis
|
$
|
1,980
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
1,980
|
|
|
|
March 31,
2018
|
||
|
Outstanding at December 31, 2017
|
$
|
1,126
|
|
|
Increase (decrease) attributed to:
|
|
|
|
|
Customer loyalty net deferrals
|
1,790
|
|
|
|
Customer loyalty redemptions
|
(1,445
|
)
|
|
|
Outstanding at March 31, 2018
|
$
|
1,471
|
|
|
|
Three Months Ended
March 31, 2018 |
|
Three Months Ended
March 31, 2017 |
|
Change
|
|||||||||||||||
|
|
Total
dollars |
|
Percent of
net sales |
|
Total
dollars |
|
Percent of
net sales |
|
Total
dollars |
|
Percentage
|
|||||||||
|
Net sales
|
$
|
87,342
|
|
|
100.0
|
%
|
|
$
|
83,098
|
|
|
100.0
|
%
|
|
$
|
4,244
|
|
|
5.1
|
%
|
|
Cost of sales
|
(22,713
|
)
|
|
(26.0
|
)
|
|
(21,728
|
)
|
|
(26.1
|
)
|
|
(985
|
)
|
|
(4.5
|
)
|
|||
|
|
64,629
|
|
|
74.0
|
|
|
61,370
|
|
|
73.9
|
|
|
3,259
|
|
|
5.3
|
|
|||
|
Volume incentives
|
31,362
|
|
|
35.9
|
|
|
28,983
|
|
|
34.9
|
|
|
2,379
|
|
|
8.2
|
|
|||
|
SG&A expenses
|
32,386
|
|
|
37.1
|
|
|
30,336
|
|
|
36.5
|
|
|
2,050
|
|
|
6.8
|
|
|||
|
Operating income
|
881
|
|
|
1.0
|
|
|
2,051
|
|
|
2.5
|
|
|
(1,170
|
)
|
|
(57.0
|
)
|
|||
|
Other income, net
|
740
|
|
|
0.8
|
|
|
1,275
|
|
|
1.5
|
|
|
(535
|
)
|
|
(42.0
|
)
|
|||
|
Income before income taxes
|
1,621
|
|
|
1.9
|
|
|
3,326
|
|
|
4.0
|
|
|
(1,705
|
)
|
|
(51.3
|
)
|
|||
|
Provision for income taxes
|
1,288
|
|
|
1.5
|
|
|
1,463
|
|
|
1.8
|
|
|
(175
|
)
|
|
(12.0
|
)
|
|||
|
Net income
|
$
|
333
|
|
|
0.4
|
%
|
|
$
|
1,863
|
|
|
2.2
|
%
|
|
$
|
(1,530
|
)
|
|
(82.1
|
)%
|
|
|
Net Sales by Operating Segment
|
||||||||||||||||
|
|
Three Months Ended
March 31, 2018 |
|
Three Months Ended
March 31, 2017 |
|
Percent
Change |
|
Impact of
Currency Exchange |
|
Percent
Change Excluding Impact of Currency |
||||||||
|
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
NSP North America
|
$
|
35,605
|
|
|
$
|
38,046
|
|
|
(6.4
|
)%
|
|
$
|
128
|
|
|
(6.8
|
)%
|
|
NSP Latin America
|
6,267
|
|
|
6,599
|
|
|
(5.0
|
)
|
|
128
|
|
|
(7.0
|
)
|
|||
|
|
41,872
|
|
|
44,645
|
|
|
(6.2
|
)
|
|
256
|
|
|
(6.8
|
)
|
|||
|
NSP Russia, Central and Eastern Europe
|
9,551
|
|
|
8,446
|
|
|
13.1
|
|
|
236
|
|
|
10.3
|
|
|||
|
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
Synergy Asia Pacific
|
23,707
|
|
|
18,781
|
|
|
26.2
|
|
|
1,531
|
|
|
18.1
|
|
|||
|
Synergy Europe
|
5,656
|
|
|
5,925
|
|
|
(4.5
|
)
|
|
754
|
|
|
(17.3
|
)
|
|||
|
Synergy North America
|
2,454
|
|
|
2,607
|
|
|
(5.9
|
)
|
|
—
|
|
|
(5.9
|
)
|
|||
|
|
31,817
|
|
|
27,313
|
|
|
16.5
|
|
|
2,285
|
|
|
8.1
|
|
|||
|
NSP China
|
4,102
|
|
|
2,694
|
|
|
52.3
|
|
|
264
|
|
|
42.5
|
|
|||
|
|
$
|
87,342
|
|
|
$
|
83,098
|
|
|
5.1
|
%
|
|
$
|
3,041
|
|
|
1.4
|
%
|
|
Three Months Ended March 31,
|
2018
|
|
2017
|
||||||||||
|
NSP Americas:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
17,746
|
|
|
42.4
|
%
|
|
$
|
19,866
|
|
|
44.5
|
%
|
|
Immune
|
5,544
|
|
|
13.2
|
|
|
5,073
|
|
|
11.4
|
|
||
|
Cardiovascular
|
3,100
|
|
|
7.4
|
|
|
3,316
|
|
|
7.4
|
|
||
|
Digestive
|
11,712
|
|
|
28.0
|
|
|
12,148
|
|
|
27.2
|
|
||
|
Personal care
|
1,825
|
|
|
4.4
|
|
|
1,886
|
|
|
4.2
|
|
||
|
Weight management
|
1,945
|
|
|
4.6
|
|
|
2,356
|
|
|
5.3
|
|
||
|
Total NSP Americas
|
41,872
|
|
|
100.0
|
|
|
44,645
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
NSP Russia, Central and Eastern Europe:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
4,131
|
|
|
43.3
|
%
|
|
$
|
3,943
|
|
|
46.7
|
%
|
|
Immune
|
1,029
|
|
|
10.8
|
|
|
862
|
|
|
10.2
|
|
||
|
Cardiovascular
|
695
|
|
|
7.3
|
|
|
595
|
|
|
7.0
|
|
||
|
Digestive
|
2,431
|
|
|
25.5
|
|
|
2,088
|
|
|
24.7
|
|
||
|
Personal care
|
960
|
|
|
10.1
|
|
|
642
|
|
|
7.6
|
|
||
|
Weight management
|
305
|
|
|
3.2
|
|
|
316
|
|
|
3.7
|
|
||
|
Total NSP Russia, Central and Eastern Europe
|
9,551
|
|
|
100.0
|
|
|
8,446
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
Synergy WorldWide:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
8,640
|
|
|
27.2
|
%
|
|
$
|
6,687
|
|
|
24.5
|
%
|
|
Immune
|
149
|
|
|
0.5
|
|
|
121
|
|
|
0.4
|
|
||
|
Cardiovascular
|
13,330
|
|
|
41.9
|
|
|
11,103
|
|
|
40.7
|
|
||
|
Digestive
|
3,825
|
|
|
12.0
|
|
|
3,465
|
|
|
12.7
|
|
||
|
Personal care
|
2,140
|
|
|
6.7
|
|
|
2,067
|
|
|
7.6
|
|
||
|
Weight management
|
3,733
|
|
|
11.7
|
|
|
3,870
|
|
|
14.2
|
|
||
|
Total Synergy WorldWide
|
31,817
|
|
|
100.0
|
|
|
27,313
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
NSP China:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
343
|
|
|
8.4
|
%
|
|
$
|
495
|
|
|
18.4
|
%
|
|
Immune
|
146
|
|
|
3.6
|
|
|
47
|
|
|
1.7
|
|
||
|
Cardiovascular
|
561
|
|
|
13.7
|
|
|
517
|
|
|
19.2
|
|
||
|
Digestive
|
2,456
|
|
|
59.9
|
|
|
1,431
|
|
|
53.1
|
|
||
|
Personal care
|
253
|
|
|
6.2
|
|
|
42
|
|
|
1.6
|
|
||
|
Weight management
|
343
|
|
|
8.4
|
|
|
162
|
|
|
6.0
|
|
||
|
Total NSP China
|
4,102
|
|
|
100.0
|
|
|
2,694
|
|
|
100.0
|
|
||
|
|
|
|
|
|
|
|
|
||||||
|
Consolidated:
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General health
|
$
|
30,860
|
|
|
35.3
|
%
|
|
$
|
30,991
|
|
|
37.3
|
%
|
|
Immune
|
6,868
|
|
|
7.9
|
|
|
6,103
|
|
|
7.3
|
|
||
|
Cardiovascular
|
17,686
|
|
|
20.2
|
|
|
15,531
|
|
|
18.7
|
|
||
|
Digestive
|
20,424
|
|
|
23.4
|
|
|
19,132
|
|
|
23.0
|
|
||
|
Personal care
|
5,178
|
|
|
5.9
|
|
|
4,637
|
|
|
5.6
|
|
||
|
Weight management
|
6,326
|
|
|
7.2
|
|
|
6,704
|
|
|
8.1
|
|
||
|
Total Consolidated
|
$
|
87,342
|
|
|
100.0
|
%
|
|
$
|
83,098
|
|
|
100.0
|
%
|
|
|
2018
|
|
2017
|
||||||||
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
||||
|
NSP Americas
|
226,700
|
|
|
6,500
|
|
|
263,700
|
|
|
7,300
|
|
|
NSP Russia, Central and Eastern Europe
|
140,700
|
|
|
3,500
|
|
|
139,800
|
|
|
3,100
|
|
|
Synergy WorldWide
|
109,700
|
|
|
3,700
|
|
|
115,200
|
|
|
4,500
|
|
|
|
477,100
|
|
|
13,700
|
|
|
518,700
|
|
|
14,900
|
|
|
|
2018
|
|
2017
|
||||||||
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
||||
|
NSP Americas
|
107,700
|
|
|
6,500
|
|
|
123,500
|
|
|
7,300
|
|
|
NSP Russia, Central and Eastern Europe
|
69,100
|
|
|
3,500
|
|
|
64,700
|
|
|
3,100
|
|
|
Synergy WorldWide
|
47,300
|
|
|
3,700
|
|
|
46,100
|
|
|
4,500
|
|
|
|
224,100
|
|
|
13,700
|
|
|
234,300
|
|
|
14,900
|
|
|
|
2018
|
|
2017
|
||||||||
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
||||
|
NSP Americas
|
21,700
|
|
|
800
|
|
|
28,300
|
|
|
1,100
|
|
|
NSP Russia, Central and Eastern Europe
|
10,500
|
|
|
200
|
|
|
12,900
|
|
|
200
|
|
|
Synergy WorldWide
|
15,600
|
|
|
800
|
|
|
11,200
|
|
|
700
|
|
|
|
47,800
|
|
|
1,800
|
|
|
52,400
|
|
|
2,000
|
|
|
|
2018
|
|
2017
|
||||||||
|
|
Distributors
& Customers |
|
Managers
|
|
Distributors
& Customers |
|
Managers
|
||||
|
NSP Americas
|
78,200
|
|
|
2,300
|
|
|
113,700
|
|
|
3,600
|
|
|
NSP Russia, Central and Eastern Europe
|
38,200
|
|
|
700
|
|
|
46,600
|
|
|
600
|
|
|
Synergy WorldWide
|
67,900
|
|
|
2,900
|
|
|
66,200
|
|
|
3,100
|
|
|
|
184,300
|
|
|
5,900
|
|
|
226,500
|
|
|
7,300
|
|
|
|
Three Months Ended March 31,
|
||||||
|
|
2018
|
|
2017
|
||||
|
Operating activities
|
$
|
3,714
|
|
|
$
|
774
|
|
|
Investing activities
|
(489
|
)
|
|
(2,189
|
)
|
||
|
Financing activities
|
(5,194
|
)
|
|
943
|
|
||
|
|
|
|
With Strengthening of U.S. Dollar by:
|
|||||||||||||||||||||
|
|
|
|
10%
|
|
15%
|
|
25%
|
|||||||||||||||||
|
|
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|||||||||||
|
Net sales
|
$
|
87,342
|
|
|
$
|
(3,766
|
)
|
|
(4.3
|
)%
|
|
$
|
(5,403
|
)
|
|
(6.2
|
)%
|
|
$
|
(8,284
|
)
|
|
(9.5
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Cost and expenses
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Cost of sales
|
22,713
|
|
|
(1,147
|
)
|
|
(5.0
|
)
|
|
(1,646
|
)
|
|
(7.2
|
)
|
|
(2,523
|
)
|
|
(11.1
|
)
|
||||
|
Volume incentives
|
31,362
|
|
|
(1,497
|
)
|
|
(4.8
|
)
|
|
(2,149
|
)
|
|
(6.9
|
)
|
|
(3,294
|
)
|
|
(10.5
|
)
|
||||
|
Selling, general and administrative
|
32,386
|
|
|
(977
|
)
|
|
(3.0
|
)
|
|
(1,401
|
)
|
|
(4.3
|
)
|
|
(2,149
|
)
|
|
(6.6
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Operating income
|
$
|
881
|
|
|
$
|
(145
|
)
|
|
(16.5
|
)%
|
|
$
|
(207
|
)
|
|
(23.5
|
)%
|
|
$
|
(318
|
)
|
|
(36.1
|
)%
|
|
|
|
|
With Strengthening of U.S. Dollar by:
|
|||||||||||||||||||||
|
|
|
|
10%
|
|
15%
|
|
25%
|
|||||||||||||||||
|
|
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|
($)
|
|
(%)
|
|||||||||||
|
Financial Instruments Included in Current Assets Subject to Exchange Rate Risk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Cash and cash equivalents
|
$
|
42,303
|
|
|
$
|
(3,129
|
)
|
|
(7.4
|
)%
|
|
$
|
(4,489
|
)
|
|
(10.6
|
)%
|
|
$
|
(6,884
|
)
|
|
(16.3
|
)%
|
|
Accounts receivable, net
|
8,259
|
|
|
(416
|
)
|
|
(5.0
|
)
|
|
(597
|
)
|
|
(7.2
|
)
|
|
(915
|
)
|
|
(11.1
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Financial Instruments Included in Current Liabilities Subject to Exchange Rate Risk
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
|
Accounts payable
|
5,143
|
|
|
(111
|
)
|
|
(2.2
|
)
|
|
(159
|
)
|
|
(3.1
|
)
|
|
(244
|
)
|
|
(4.7
|
)
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
Net Financial Instruments Subject to Exchange Rate Risk
|
$
|
45,419
|
|
|
$
|
(3,434
|
)
|
|
(7.6
|
)%
|
|
$
|
(4,927
|
)
|
|
(10.8
|
)%
|
|
$
|
(7,555
|
)
|
|
(16.6
|
)%
|
|
|
|
Translated into U.S.
Dollars |
|
At Spot Exchange Rate
per One U.S. Dollar as of March 31, 2018 |
|||
|
Cash and cash equivalents
|
|
|
|
|
|
|
|
|
South Korea (Won)
|
|
$
|
9,794
|
|
|
1,061.9
|
|
|
Hong Kong (Dollar)
|
|
5,665
|
|
|
0.8
|
|
|
|
European Markets (Euro)
|
|
3,004
|
|
|
106.2
|
|
|
|
Japan (Yen)
|
|
2,576
|
|
|
7.8
|
|
|
|
China (Yuan Renminbi)
|
|
1,631
|
|
|
6.3
|
|
|
|
Malaysia (Ringgit)
|
|
1,509
|
|
|
3.9
|
|
|
|
Poland (Zloty)
|
|
1,376
|
|
|
3.4
|
|
|
|
Canada (Dollar)
|
|
1,261
|
|
|
1.3
|
|
|
|
Thailand (Baht)
|
|
1,046
|
|
|
31.2
|
|
|
|
Other
|
|
6,556
|
|
|
Varies
|
|
|
|
Total foreign denominated cash and cash equivalents
|
|
34,418
|
|
|
|
|
|
|
U.S. dollars held by foreign subsidiaries
|
|
1,255
|
|
|
|
|
|
|
Total cash and cash equivalents held by foreign subsidiaries
|
|
$
|
35,673
|
|
|
|
|
|
Three Months Ended March 31,
|
|
2018
|
|
2017
|
||
|
Canada (Dollar)
|
|
1.3
|
|
|
1.3
|
|
|
European Markets (Euro)
|
|
0.8
|
|
|
0.9
|
|
|
Japan (Yen)
|
|
108.3
|
|
|
113.8
|
|
|
South Korea (Won)
|
|
1,072.1
|
|
|
1,154.9
|
|
|
Mexico (Peso)
|
|
18.7
|
|
|
20.3
|
|
|
Item No.
|
|
Exhibit
|
|
31.1(1)
|
|
|
|
31.2(1)
|
|
|
|
32.1(1)
|
|
|
|
32.2(1)
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
Nature's Sunshine Products, Inc.
|
||
|
|
|
|
|
Date:
|
May 10, 2018
|
/s/ Gregory L. Probert
|
|
|
|
Gregory L. Probert,
|
|
|
|
Chief Executive Officer and Chairman of the Board
|
|
|
|
|
|
|
|
|
|
Date:
|
May 10, 2018
|
/s/ Joseph W. Baty
|
|
|
|
Joseph W. Baty,
|
|
|
|
Executive Vice President, Chief Financial Officer and Treasurer
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|